Silence Therapeutics (SLN) Gains from Investment Securities (2021 - 2026)

Silence Therapeutics has disclosed Gains from Investment Securities across 6 years of filings, most recently posting -$88000.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at -$88000.0, down 101.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (up 96.45% YoY), and the FY2025 annual result was $7.0 million, down 60.12% from the prior year.
• Gains from Investment Securities came in at -$88000.0 for Q1 2026 at Silence Therapeutics, down from $7.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.6 million in Q4 2022 to a low of -$258000.0 in Q2 2024.
• The 5-year median for Gains from Investment Securities is $6.6 million (2023), against an average of $4.5 million.
• Across the five-year window, Gains from Investment Securities jumped 38730.15% in 2025 and sank 101.2% in 2026, its largest moves.
• Silence Therapeutics' Gains from Investment Securities stood at $13.6 million in 2022, then sank by 51.68% to $6.6 million in 2023, then climbed by 8.65% to $7.1 million in 2024, then grew by 4.27% to $7.4 million in 2025, then slumped by 101.18% to -$88000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$88000.0 (Q1 2026), $7.4 million (Q4 2025), and $423551.0 (Q3 2025), per Business Quant data.